All the top Biotech & Pharma news in one daily newsletter.

Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

THE GOOD
Approvals & Labels

FDA approves J&J's Darzalex Faspro (daratumumab) combination for newly diagnosed multiple myeloma patients ineligible for transplant
Monoclonal antibody, cancer, multiple myeloma, CD38 target, combination therapy, subcutaneous formulation - Read more

THE GOOD
Business Development & Partnerships

Insilico Medicine, Qilu Pharmaceutical partner on AI-driven cardiometabolic disease discovery worth $120M
Research collaboration, cardiometabolic, AI/ML, small molecule, R&D - Read more

Oath Surgical, Nvidia partner on AI infrastructure for outpatient surgery centers, financial terms undisclosed
Technology partnership, AI/ML, digital health, surgical technology - Read more

Boehringer Ingelheim, Simcere Pharmaceutical partner on IBD bispecific antibody SIM0709, up to $1.26B total
Licensing deal, autoimmune, bispecific antibody, milestone payments - Read more

Gedeon Richter UK takes over UK marketing rights for schizophrenia drug cariprazine from Recordati Pharmaceuticals
Licensing deal, neurological, commercialization, small molecule - Read more

BioMed X, Government of Barbados partner on AI-enabled diabetic kidney disease research project
Research collaboration, AI/ML, cardiometabolic disease, drug discovery, biomarker discovery - Read more

Siegfried acquires Noramco Group and Extractas Bioscience facilities from SK Capital, advancing US expansion strategy
Small molecule, strategic, major transaction, operational - Read more

PRESENTED BY SCIENCE 2 SALES
We book your meetings. You close the deals.

If you’re selling into biotech or pharma, your highly qualified BD reps should be closing deals and not spending hours cold calling and cold emailing.

Science 2 Sales handles the entire outbound motion - cold calls, emails, and LinkedIn outreach - delivering qualified meetings that actually convert. We speak your prospects' scientific language, so the conversations start at a higher level.

The result? Your pipeline stays full while your reps focus on revenue.

We offer a 30 day money back guarantee on your first month - if we don't deliver, you don't pay.

Book a free strategy call to see how we can help.

✅ More Good News ✅

THE GOOD
Clinical Trials

Roche's CT-388 achieves 22.5% weight loss in Ph2 obesity trial, advancing to Ph3 development
Small molecule, metabolic, GLP-1/GIP receptor agonist, obesity, dual agonist, combination therapy - Read more

Cardiff Oncology reports positive Ph2 results for onvansertib targeting PLK1 in metastatic colorectal cancer
Small molecule, cancer, PLK1 inhibitor, metastatic colorectal cancer, RAS mutation, combination therapy - Read more

THE GOOD
Company Launches

Baseline Therapeutics launches to test GLP-1 drug BT-001 for alcohol use disorder, challenging Eli Lilly
GLP-1 receptor agonist, addiction disorders, strategic, competitive - Read more

THE GOOD
Earnings & Finances

Servier achieves 16% revenue growth to €6.9B ($8.19B), advances toward ambitious €10B ($11.87B) goal by 2030
Small molecule, oncology, financial, revenue impact - Read more

THE GOOD
Fundraises

TRexBio raises $50M Series B extension, testing eczema drug TRB-061
Autoimmune, regulatory T cell platform, atopic dermatitis, clinical-stage - Read more

Epidarex raises $145M Fund IV, early-stage UK-US life science investing
Venture capital, early-stage investing, therapeutics, medical devices - Read more

Biomind Labs raises CAD $2.5M ($1.8M) private placement, advancing clinical-stage biopharmaceutical programs
Clinical-stage, neurological, biopharmaceutical, neuroscience - Read more

THE GOOD
Market Reports

Pfizer retains top spot in physician vaccine maker rankings while Sanofi drops to seventh place
Vaccine, infectious disease, competitive, strategic - Read more

THE GOOD
Mergers & Acquisitions

Mirum Pharmaceuticals completes acquisition of Bluejay Therapeutics, gaining brelovitug for chronic hepatitis delta virus treatment
Monoclonal antibody, rare disease, strategic, major transaction - Read more

THE GOOD
Politics & Policy

EU and India agree to sweeping free trade pact eliminating 11% tariff on pharmaceutical exports
Pharmaceuticals, strategic, major transaction, operational - Read more

THE GOOD
Regulatory

CMS unveils 15 high-profile drugs including GSK's Anoro, Gilead's Biktarvy for IRA price negotiations
Multiple modalities, multiple diseases, regulatory, major transaction, cost reduction - Read more

FDA lifts clinical hold on Intellia Therapeutics' MAGNITUDE-2 Phase III trial for ATTR gene editing treatment
Gene editing, rare disease, regulatory, operational - Read more

FDA greenlights Life Biosciences' gene therapy study testing cellular 'reset' for aging reversal
Gene therapy, longevity, regulatory, strategic - Read more [paywall]

PRESENTED BY YOU?
Get the attention of 2500+ Biotech & Pharma Professionals 🤩

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

THE BAD
Clinical Trials

AstraZeneca terminates AZD0233 Ph1 trial targeting CX3CR1 receptor for dilated cardiomyopathy due to toxicology findings
Small molecule, cardiovascular, heart failure, dilated cardiomyopathy, CX3CR1 receptor - Read more

THE BAD
Regulatory

China regulators suspend Sun Pharma's dementia drug sales after finding manufacturing quality deficiencies
Small molecule, neurological, regulatory, operational - Read more

THE BAD
Strategic Plans

Genenta Science rebrands as Saentra Forge, pivots from gene therapies to acquire Italian weapons manufacturer ATC
Cell-based gene therapy, oncology, strategic, major transaction - Read more

THE UGLY
No Ugly News Today!

You’re all caught up on the latest Pharma & Biotech News!

TLDR Biotech wants to hear from you! 📣

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here